Introduction
Sinonasal carcinomas are relatively rare, representing < 5% of all head and neck cancers. Treatment options are limited due to the presence of tumors near the risk organs (eyes, optic nerve, chiasma opticum, brain, brain stem, pituitary gland). Achieving maximum local control through radical treatment while minimizing its consequences is a considerable challenge facing this group of tumors. Patients with an early form of the disease are treated surgically, either endoscopically or through an open procedure. Locally advanced tumors require a multidisciplinary approach – surgery followed by radiotherapy in resectable tumors, or definitive radiotherapy ± chemotherapy in unresectable tumors [1].
In retrospective evaluations, N-staging was found to be the strongest prognostic factor with negative impact of regional spread on tumor control and survival [2–8]. Other prognostic factors reported in retrospective studies are: age [2, 3, 8, 11]; sex [2, 8]; race [12]; performance status [13]; smoking [13]; comorbidities [14]; T-staging [2, 3, 5, 6, 8, 11, 15, 16]; clinical stage [6, 10]; intracranial extension [4,5,17]; intraorbital extension [3,17,18]; invasion to lamina cribriformis [12, 15, 17]; infratemporal fossae extension [16]; invasion of the dura mater [16]; sublocality [16]; histological type [5, 12, 16]; tumor cell differentiation [8, 19]; neuroinvasion [18]; surgical resection [2–4, 6, 10, 16]; radicality of resection [2]; total dose of radiotherapy [2, 3, 20]; total time of radiotherapy [2]; and; chemotherapy [11].
In this study we aim to analyze long-term treatment outcomes and toxicity in a consecutive group of patients treated with curative radiotherapy at Institute of Radiation Oncology and identify prognostic factors that affect treatment results.
Materials and methods
Over the period of January 2002 to December 2018, 83 patients were treated for nasal cavity and paranasal sinus tumors. 22 patients were excluded (palliative treatment for bad general conditions 11, metastatic disease 4, synchronous tumor in the head neck region 1, sarcoma 4, ameloblastoma 2). In the study, all 61 consecutive patients with sinonasal carcinoma who started postoperative or definitive radiotherapy with a curative intent were included. The median follow-up was 53 months. The median age at the time of treatment initiation was 59 years (32–85). The female to male ratio was 1: 2.8. Most patients were smokers or former smokers (71%); about a third of patients admitted to daily alcohol consumption. A significant proportion of patients had severe comorbidities; the Adult Comorbidity Evaluation score 27 (ACE-27) was ≥ 1 in 48% of patients. All tumors were retrospectively reclassified according to the 7th version of the tumour–nodes–metastases (TNM) classification. The majority of patients were treated for locally advanced disease (85% clinical stage ≥ III). In 23 patients (38%), the tumor propagated into the orbit. Regional cervical metastases were initially diagnosed in 23% of patients. Squamous cell carcinoma was the most frequent histology (Tab. 1).
|
Parameter |
n |
% |
|
Age (y) Median |
(32–85) 59.19 |
|
|
Sex Males Females |
45 16 |
74 26 |
|
Smoking Chronic nicotinism Former (> 5 years) Non-smoker Unknown |
29 14 16 2 |
48 23 26 3 |
|
Alcohol Daily Occasionally None Unknown |
20 33 7 1 |
33 54 11 2 |
|
Comorbidities ACE 0 ACE 1 ACE 2 ACE 3 Unknown |
31 15 11 3 1 |
51 25 18 5 2 |
|
Locality Nasal cavity Sinus maxillaris Sinus ethmoidalis Sinus frontalis |
16 41 3 1 |
26 67 5 2 |
|
T-staging T1 T2 T3 T4a T4b |
3 9 15 21 13 |
5 15 25 34 21 |
|
N-staging N0 N1 N2a N2b N2c N3 |
47 3 0 6 4 1 |
77 5 0 10 6 2 |
|
Clinical stage I II III IVA IVB |
3 6 15 23 14 |
5 10 24 39 23 |
|
Histological type Epidermoid carcinoma Undifferentiated carcinoma Adenoid-cystic carcinoma Schneiderian membrane carcinoma Adenocarcinoma Neuroendocrine carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma Small cell carcinoma Olfactory neuroblastoma |
37 8 7 2 2 1 1 1 1 1 |
61 13 11 3 3 2 2 2 2 2 |
|
Primary tumor Local recurrence |
53 8 |
87 13 |
|
Grading G1 G2 G3/4 Unknown |
4 18 27 12 |
7 30 44 20 |
Treatment
Surgery
In 39 (64%) patients, radiotherapy was preceded by resection of the primary tumor; 12 of these patients underwent bilateral or unilateral neck dissection. A total of 8 patients underwent endoscopic resection for the primary tumor (ethmoidal sinus 1, maxillary sinus 2, nasal cavity 5). Other patients underwent open surgical approaches. An orbital exenteration was performed in 6 patients with tumor spread to the orbit. Full radicality (resection margins ≥ 5 mm) was declared only in 26% of patients who underwent resection. In the rest of the patients, surgery was limited to biopsy verification.
Radiotherapy
Before 2007, patients were treated with 2D and 3D conformal radiotherapy (19 cases). Patients were treated with the intensity-modulated radiation therapy (IMRT) technique from 2007 onwards (42 cases). In the first phase clinical target volume (CTV) included the tumor/bed and the entire paranasal cavity and other risky parts of the sinonasal system & regional lymph nodes in T3/4 and N+ tumors (areas Ib–III ± retropharyngeal). The decision on unilateral or bilateral irradiation of the neck was made on the basis of initial clinical indicators (tumor localization, spread of the tumor across the midline, etc.). In the second phase, the tumor/bed and entire paranasal cavity & areas with initial lymphadenopathy were irradiated. Prescribed dose was 56 Gy/28 fractions for definitive radiotherapy or 50 Gy/25 fractions for postoperative radiotherapy (first phase) and 14 Gy/7 fractions (second phase). Organs at risk and dose constrains are shown in Table 3.The median total dose was 70 Gy. Irradiation of regional lymph nodes was given to 37 patients (61%). Of the 47 patients with initial N0 staging, 23 had regional areas irradiated (18 bilaterally, 5 unilaterally). Of the 14 patients with initial N+ staging, 12 had the regional areas irradiated bilaterally and 2 unilaterally).
|
OAR |
Dose constraints |
Auxiliary crieria |
|
Spinal cord |
Dmax ≤ 5000 cGy |
|
|
Brainstem |
Dmax ≤ 5400 cGy |
V55 Gy 1–5% |
|
Optic nerve |
Dmax ≤ 5400 cGy |
|
|
Optic chiasm |
Dmax ≤ 5400 cGy |
V55 Gy 1–5% |
|
Cochlea |
Dmax < 6000 cGy |
Dmax < 3500 cGy contralateral |
|
Brain |
Dmed < 3500 cGy |
|
|
Temporal lobe |
Dmax < 2200 cGy |
|
|
Parotid glands |
Dmean ≤ 2800 cGy |
|
Chemotherapy
A total of 29 patients (48%) received chemotherapy, 27 of them with cisplatin 40 mg/m2 weekly concomitantly. 4 patients received neoadjuvant chemotherapy based on platinum derivatives (all received concomitant chemotherapy as well). The median cumulative cisplatin dose in concomitant chemotherapy was 200 mg/m2. 2 patients (small cell carcinoma 1, neuroendocrine carcinoma 1) were treated with chemotherapy in combination cisplatin + etoposide. The basic characteristics of the treatment are summarized in Table 2.
|
Treatment |
n |
% |
|
Surgery Radical surgery No surgery |
39 22 |
64 36 |
|
Type of surgery Endoscopically Open resection |
39 8 31 |
100 21 79 |
|
Radicality of resection R0 (³ 5 mm) R0 (> 1 < 5mm) R1 (0 ≤ 1 mm) R2 RX |
39 10 2 17 3 7 |
100 26 5 44 8 18 |
|
Neck dissection Unilateral Bilateral |
11 1 |
18 2 |
|
Radiotherapy Postoperative Definitive |
39 22 |
64 36 |
|
Radiotherapy technique 2D/3D-CRT IMRT |
19 42 |
31 69 |
|
Regional radiotherapy N+ N0 |
37 14 23 |
61 23 38 |
|
Total irradiation dose [Gy] Median Mean |
(18–72) 70 64.13 |
|
|
Chemotherapy Concomitant Adjuvant Neoadjuvant + concomitant No chemotherapy |
23 2 4 32 |
38 3 7 52 |
|
Concomitant chemotherapy Number of cycles — median (n) ≥ 5 cycles < 5 cycles |
27 |
|
|
5 |
||
|
14 13 |
67 33 |
|
Analysis
For statistical analysis, all data were recorded and analyzed on XLSTAT software (Addinsoft) version 18.07. Kaplan-Meier methods were used to estimate locoregional control (LRC), distant metastasis-free interval (DMFI), overall survival (OS), and disease-free survival (DFS). The survival or disease-free periods counted from the start of radiation to the time of relapse (LRC, DMFI) or death (OS) or relapse and death (DFS). The log-rank test was used to compare survival and recurrence rates between various parameters. We used the Cox regression hazard model to analyze multivariate data. All analyses were performed with a two-sided significance level of ≤ 0.05. Acute and late toxicity were evaluated according to Radiation Therapy Oncology Group (RTOG) criteria [21]. Comorbidities present at the time of diagnosis were collected retrospectively using the ACE-27 index [22].
Results
Acute toxicity
All patients were assessed for acute radiation toxicity (Tab. 4). Severe radiation mucositis (grade 3/4) was observed in 21% of treated patients. Severe radiation dermatitis was not observed in this cohort. Severe grade 3 ocular toxicity occurred in 2 patients. Serious swallowing difficulties (grade 3) were reported in 15% of patients. The average weight loss was 5.2 kg (7% of the input weight). All patients were assessed for hematological toxicity as well. 3% of patients had severe neutropenia (grade 3), 3% had severe anemia (grade 3). In summary, all severe acute toxicities occurred during treatment or within three months of treatment in 22 patients (36%). Two patients died during treatment (extensive myocardial infarction 1, septic complications 1).
|
Acute radiation toxicity |
||||||||
|
N = 61 |
Mucous membrane |
Skin |
Salivary gland |
Eye |
Ear |
Larynx |
Pharynx/Esophagus |
Upper GI |
|
Grade 0 |
5% |
7% |
25% |
37% |
90% |
86% |
39% |
19% |
|
Grade 1 |
23% |
44% |
42% |
37% |
7% |
14% |
27% |
26% |
|
Grade 2 |
51% |
49% |
33% |
23% |
3% |
0% |
19% |
42% |
|
Grade 3 |
16% |
0% |
– |
3% |
0% |
0% |
15% |
12% |
|
Grade 4 |
5% |
0% |
0% |
0% |
0% |
0% |
0% |
0% |
|
Late radiation toxicity |
|||||||||
|
N = 48 |
Mucous membrane |
Skin |
Subcutaneous tissue |
Salivary gland |
Eye |
Larynx |
Pharynx |
Brain |
Spinal cord |
|
Grade 0 |
32% |
35% |
56% |
23% |
67% |
100% |
75% |
96% |
100% |
|
Grade 1 |
56% |
60% |
33% |
42% |
17% |
0% |
17% |
2% |
0% |
|
Grade 2 |
10% |
5% |
8% |
29% |
4% |
0% |
8% |
0% |
0% |
|
Grade 3 |
2% |
0% |
2% |
6% |
6% |
0% |
0% |
0% |
0% |
|
Grade 4 |
0% |
0% |
0% |
0% |
6% |
0% |
0% |
2% |
0% |
Late toxicity
The late toxicity of the treatment could be assessed in 48 patients (92% of survivors > 3 months post-treatment). Severe late toxicity was expressed in 11 patients (23% of the evaluated number of patients). Severe late ocular toxicity was more prevalent (grade 3/4 in 12% of surviving patients), which led to amaurosis in 3 patients. In the first patient treated for neuroendocrine carcinoma of the nasal cavity, 2D postoperative radiotherapy was administered up to a dose of 70 Gy; ocular toxicity developed 4 months after the end of treatment, resulting in bulb evisceration 26 months following the completion of radiotherapy. The second patient was treated for olfactory neuroblastoma of the nasal cavity and paranasal sinuses with postoperative IMRT radiotherapy up to 70 Gy; 10 months following end of radiotherapy, the patient developed a trophic corneal ulcer which was resolved by eviscerating the bulb 42 months following the end of radiotherapy. The third patient was treated for adenoid-cystic carcinoma of the maxillary sinus with definitive IMRT radiotherapy up to 70 Gy; 6 months after radiotherapy, the patient developed a corneal ulcer and secondary glaucoma, resulted in total amaurosis 13 months after radiotherapy ended. Three cases of severe grade 3 ocular toxicity have been reported in patients treated for maxillary sinus carcinoma 2D (1) and IMRT (2) at intervals of 6, 34, and 55 months after treatment ended. 2 patients developed osteoradionecrosis 134 months (2D postoperative chemoradiotherapy up to 70 Gy) and 12 months after treatment (IMRT postoperative chemoradiotherapy up to 70 Gy). In both cases, osteoradionecrosis required surgical treatment. None of the 26 patients who had prophylactically introduced percutaneous endoscopic gastrostomy remained permanently fully PEG-dependent. One patient developed brain necrosis; the treatment was conservative. No patients suffered severe spinal toxicity (Tab. 4).
Locoregional control
A total of 20 local failures were detected in 18 patients (30%). There was local persistence in 7 patients after the end of treatment (initially 1 T2, 5 T4a, 1 T4b); 11 patients failed locally during follow-up (initially 1 T1, 1 T2, 2 T3, 3 T4a, 4 T4b). Only one patient (squamous cell carcinoma of the maxillary sinus initially T4aN2b) failed regionally at the site of initial presentation 4 months after the end of radiotherapy. The majority of locoregional failures (79%) were detected in the first 36 months after the end of radiotherapy (range 2–84 months). Five-year and ten-year locoregional control was 74% and 67%, respectively (Fig. 1). A total of 7 patients (37%) underwent salvage surgery out of the 18 patients with local failure. After the detection of local failure, 2 patients died 51 and 105 months later, while 5 patients survived after salvage surgery 20, 55, 62, 140, and 203 months later. One patient who had regional failure died after undergoing reirradiation 8 months after detection of the recurrence. 2 patients were treated with palliative chemotherapy and died 3 and 29 months after recurrence. The remaining 9 patients received only symptomatic treatment.
Distant control
Distant failure was reported in 6 patients (10%), including 5 patients within 36 months following completion of radiotherapy (range 5.8–39.4 months). 90% of patients did not develop distant metastases after 5 and 10 years, respectively (Fig. 2). One of the six distant failure patients had brain metastasis, which was treated by neurosurgery; the patient died three months after the failure. 2 patients underwent palliative chemotherapy, the first died 14 months after the failure, and the other patient with metastases to the lungs and liver was in complete remission for a long time after palliative chemotherapy and died 59 months after the first metastases were detected. 1 patient with local recurrence and liver metastases was treated with radiofrequency ablation and lived 3 months. 2 patients were treated only symptomatically.
Survival
A total of 38 patients died. Tumor progression was the primary cause of death in 16 patients. In 20 patients, the cause of death was unrelated to cancer. During the follow-up, 4 metachronous duplicate tumors outside the head and neck area were diagnosed in 4 patients 28–85 months after treatment. Duplicate tumor progression was the cause of death in 2 of them. The 5- and 10-year overall survival was 58% and 41%, respectively (Fig. 3). The 5- and 10-year DFS was 38% and 25%, respectively.
Univariate and multivariate analysis
Parameters that reached statistical significance in the univariate analysis were: age; N-status; clinical stage; comorbidities; initial surgery; weight loss; grade 3/4 hematological toxicity and; initial response to treatment (Tab. 5). The multivariate analysis of variables showed the following independent prognostic parameters: Age for overall survival [hazard ratio (HR): 4.132; 95% confidence interval (CI): 1.529–11.166; p = 0.005], N-staging for overall survival (HR: 2.535; 95% CI: 1.096–5.859; p = 0.030) and disease-free survival (HR: 2.494; 95% CI: 1.084–5.737; p = 0.032), comorbidities for disease-free survival (HR: 4.479; 95% CI: 1.649–12,163; p = 0.003) and initial response for overall survival (HR: 4.043; 95% CI: 1.330–12.290; p = 0.014) and DFS (HR: 66.968; 95% CI: 15.119–296.239; p < 0.0001). The multivariate analysis showed a trend towards overall survival deterioration in patients of the advanced clinical stage (p = 0.065), patients with a higher ACE score (p = 0.073), and in patients who achieved severe acute hematological toxicity during treatment (p = 0.045) (Tab. 6).
|
Parametr |
Groups |
LRC |
OS |
DFS |
|
Age |
≤ 65 vs. > 65 years |
0.7219 |
0.0392 |
0.1732 |
|
Gender |
Female vs. male |
0.2363 |
0.1303 |
0.0726 |
|
Education |
Higher vs. basic |
0.6983 |
0.4721 |
0.7228 |
|
Marrital status |
Married vs. others |
0.4973 |
0.8674 |
0.4558 |
|
Locality |
Nasal cavity vs. others |
0.6279 |
0.1884 |
0.1585 |
|
Primarity |
Primary vs. recurrent |
0.5105 |
0.5567 |
0.8953 |
|
T-staging |
T1–3 vs. T4 |
0.0926 |
0.0662 |
0.1291 |
|
N-staging |
N0 vs. N+ |
0.6253 |
0.0185 |
0.0087 |
|
Stage |
I–III vs. IV |
0.0517 |
0.0227 |
0.0169 |
|
Histology |
Squamous cell vs. others |
0.5377 |
0.0746 |
0.1952 |
|
Grading |
G1/2 vs. G3 |
0.6383 |
0.5535 |
0.5527 |
|
Comorbidities |
ACE 0–1 vs. 2–3 |
0.1945 |
< 0.0001 |
0.0003 |
|
Smoking |
Non-smoker vs. smoker |
0.8246 |
0.3803 |
0.3390 |
|
Alcohol |
No/occasionally vs. daily |
0.6907 |
0.2070 |
0.0915 |
|
Duration of symptoms |
≤ 3 m vs. > 3 m |
0.9134 |
0.7563 |
0.9142 |
|
Radiotherapy |
Postoperative vs. definitive |
0.0363 |
0.2463 |
0.0704 |
|
Prolongation of radiotherapy |
≤ 3 vs. > 3 days |
0.7239 |
0.6865 |
0.6283 |
|
Total dose [Gy] |
≤ 69 vs. > 69 |
0.7521 |
0.0515 |
0.2078 |
|
Concomitant CHT |
Yes vs. no |
0.7637 |
0.5742 |
0.7472 |
|
Weight loss |
≤ 10% vs. > 10% |
0.9403 |
0.0500 |
0.3039 |
|
Anemia |
Hb ≥ 100 vs. Hb < 100 |
0.3024 |
0.2502 |
0.6776 |
|
Hematotoxicity G3/4 |
Yes vs. no |
0.7594 |
0.0447 |
0.2411 |
|
Feeding tube |
Yes vs. no |
0.1843 |
0.7713 |
0.8949 |
|
Response |
CR vs. nonCR |
< 0.0001 |
0.0109 |
< 0.0001 |
|
Epoch |
2002–2011 vs. 2012–2018 |
0.7625 |
0.4777 |
0.5683 |
|
Parametr |
Groups |
HR |
95% CI |
p-value |
|
Locoregional control |
||||
|
Radiotherapy |
Postoper vs. definitive |
1.138 |
0.381–3.041 |
0.819 |
|
Initial response |
CR vs. nonCR |
14.120 |
4.348–45.855 |
< 0.0001 |
|
0verall survival |
||||
|
Age |
≤ 65 vs. > 65 |
4.132 |
1.529–11.166 |
0.005 |
|
N-staging |
N0 vs. N+ |
2.535 |
1.096–5.859 |
0.030 |
|
Stage |
I–III vs. IV |
2.348 |
0.947–5.823 |
0.065 |
|
Comorbidities |
ACE 0–1 vs. 2-3 |
2.753 |
0.908–8.347 |
0.073 |
|
Weight loss |
≤ 10% vs. > 10% |
0.380 |
0.125–1.161 |
0.090 |
|
Hematological toxicity G3/4 |
Yes vs. no |
2.632 |
0.943 – 7.342 |
0.065 |
|
Initial response |
CR vs. nonCR |
4.043 |
1.330–12.290 |
0.014 |
|
Disease free survival |
||||
|
N-staging |
N0 vs. N+ |
2.494 |
1.084–5.737 |
0.032 |
|
Stage |
I–III vs. IV |
1.513 |
0.703–3.258 |
0.290 |
|
Comorbidities |
ACE 0–1 vs. 2–3 |
2.753 |
0.908–8.347 |
0.073 |
|
Initial response |
CR vs. nonCR |
66.968 |
15.119- 296.639 |
< 0.0001 |
Discussion
The optimal treatment of sinonasal carcinoma still remains unknown. The rareness of the disease means that there are no prospective clinical studies readily available, so we have to rely on retrospective studies, which are burdened by the heterogeneity of patients and inconsistencies in treatment procedures. Retrospective studies [2–6, 10, 12, 13, 16–18, 20, 23–26] report 5-year local control in the range of 43–80%, regional control 79–93% and distant control 66–90% (Tab. 7).
|
Study |
n |
Treatment |
LC |
RC |
DMC |
OS |
|
Jiang 1991 [23] |
73 SM 36 SCC, 20 ACC, 6 AC, 2 MEC, 9 UDC |
S + RT 100% |
78% |
84% |
77% |
– |
|
Le 1999 [2] |
97 SM 58 SCC, 4 AC, 19 ACC, 16 UDC |
S + RT 63% RT 37% |
43% |
90% |
66% |
34% |
|
Jansen 2000 [3] |
73 PNS 40 SCC, 14 AC, 8 ACC, 11 UDC |
S 4% RT 25% S + RT 68% |
63% |
79% |
86% |
46% |
|
Waldron 2000 |
110 SM SCC 95, UDC 15 |
RT 75% S + RT 25% |
43% |
– |
90% |
– |
|
Dulguerov 2001 [16] |
220 NC & PNS 66 NC, 103 SM, 38 SE 126 SCC, 35 ACC, 25 AC 30 UDC |
S 20% S + RT 46% RT 21% |
59% |
– |
– |
40% |
|
Katz 2002 [10] |
78 NC & PNS 48 NC, 24 SE 25 SCC, 31 AC + ACC + MEC 14 UDC, 8 ENB |
RT 65% S + RT 35% |
60% |
88% |
73% |
50% |
|
Blanco 2003 [4] |
106 PNS 81 SM, 19 SE 87 SCC, 14 ACC, 5 AC |
S + RT 65% RT 35% |
58% |
– |
71% |
27% |
|
39% |
||||||
|
Porceddu 2004 [18] |
60 NC & PNS 32 SCC, 25 AC, 3 UDC |
S 8% S + RT 67% RT 25% |
49% |
88% |
90% |
40% |
|
Chen 2007 [25] |
127 NC & PNS 83 SCC, 28 ACC, 28 AC |
S+RT 84% RT 16% |
62% |
– |
– |
52% |
|
Dirix 2007 [5] |
127 NC & PNS 8 NC, 45 SM, 70 SE 48 SCC, 66 AC, 3 ACC, 10 UDC |
S+RT 88% RT 12% |
53% |
93% |
75% |
54% |
|
Hoppe 2007 [12] |
85 NC & PNS 24 NC, 45 SM, 14 SE 42 SCC, 11 ACC, 6 AC 3 UDC, 9 Sa, 7 ENB |
S+RT 100% |
62% |
87% |
82% |
67% |
|
Madani 2008 [20] |
84 NC & PNS 16 NC, 19 SM, 47 SE 17 SCC, 4 ACC, 54 AC, 9 ENB |
S + RT 89% RT 11% IMRT |
71% |
– |
82% |
59% |
|
Mendenhall 2009 [6] |
109 NC & PNS 69 NC, 33 SE, 6 SS 32 SCC, 9 AC 16 ACC, 2 MEC, 14 UDC, 22 ENB |
S + RT 49% RT 51% |
63% |
91% (N0) 51% (N+) |
81% |
55% |
|
Khademi 2010 [26] |
71 NC & PNS 20 NC, 29 SM, 19 SE 19 SCC, 18 ACC, 3 AC, 5 UDC, 6 ENB |
S 21% S + RT 51% RT 28% |
60% |
– |
– |
55% |
|
Duprez 2011 [17] |
130 NC & PNS 31 NC, 24 SM, 74 SE 23 SCC, 82 AC |
S + RT 78% IMRT |
59% |
98% |
84% |
52% |
|
Russo 2016 [13] |
54 NC & PNS 7 NC, 24 SM, 9 SE, 14 SS, 54 SCC |
S + RT 69% RTp |
80% |
83% |
78% |
47% |
The majority of studies reported better treatment outcomes for patients treated with surgical resection and postoperative radiotherapy compared to radiotherapy alone. The authors from Washington University found that initial surgery had a statistically significant impact on 5-year DFS in 106 patients with paranasal sinus carcinomas treated with postoperative or definitive radiotherapy[4]. Furthermore, other retrospective studies showed that combined treatment resulted in better local control and survival [2, 3, 6, 10, 17]. Radical surgery followed by postoperative radiotherapy is therefore a generally accepted method of choice. Our cohort included mainly patients with locally advanced (39% stage IVA, 23% stage IVB, 23% N+) sinonasal carcinoma. Long-term tumor control rate has been high for most patients treated. The positive impact of the initial resection on locoregional control was recorded only in the univariate analysis (Fig. 4). In the multivariate analysis, this difference did not reach statistical significance. In the case of N0 staging, there is an ambiguous view concerning the need for elective irradiation of cervical nodes. The risk of regional involvement increases especially in patients with squamous cell and non-differentiated carcinomas and, therefore, some authors recommend irradiating regional areas of these tumors even if there are no signs of their involvement [7, 12]. In our cohort, regional nodes were irradiated in half of the treated patients. We did not detect regional failure in patients with initial N0 staging.
The benefit of chemotherapy in the curative treatment of sinonasal carcinomas has not been ascertained. In a retrospective analysis of 36 patients with squamous cell carcinoma of the maxillary sinus, adjuvant chemotherapy was statistically significant in prolonging overall survival [11]. Some studies have suggested a potential benefit of chemotherapy for patients with undifferentiated carcinoma [27]. However, due to the small number and heterogeneity of the evaluated groups, it is difficult to draw any definite conclusions. Nearly half of the patients in our study received chemotherapy, the vast majority of which was concomitant chemotherapy with a weekly regimen of cisplatin. Univariate analysis failed to demonstrate the impact of added chemotherapy on cancer control or survival.
In retrospective evaluations, N-staging was found to be the strongest prognostic factor. Regional metastases affect a minority of patients and are initially diagnosed in < 15% of patients with sinonasal carcinoma [2, 3, 12]. The Surveillance, Epidemiology, and End Results database reported only 5% of patients with regional metastases in the analysis of 783 patients with nasal carcinomas [8]. Retrospective studies have shown a negative impact of regional spread on locoregional control, distant control and overall survival [2–7]. In our study, the pre-treatment presence of regional metastases proved to be an essential prognostic factor for overall survival (HR: 2.535; 95% CI: 1.096–5.859; p = 0.030) and DFS (HR: 2.494; 95% CI: 1.084–5.737; p = 0.032) in multivariate analysis.
The prognostic significance of age has been repeatedly reported [2, 3, 8, 11]. In line with these data, we also noted a significant negative prognostic impact of age >65 years on overall survival in multivariate analysis (HR: 4.132; 95% CI: 1.529–11.166; p = 0.005).
A 5-year overall survival rate ranging from 27 to 67% was reported in retrospective trials [2–6, 10, 12, 13, 16–18, 20, 23–26] (Tab. 7). The 5-year overall survival of our group was 51%. Non-tumor mortality contributed to it to a greater extent. A large proportion of patients were affected by severe comorbidities and elements of self-destructive lifestyle. Deaths due to progression or recurrence of primary disease were recorded in less than half of the deaths. 5% of the patients died as a result of progression of their duplicate tumors. Various methodologies, including ACE-27, have repeatedly demonstrated the significant prognostic significance of comorbidities in patients with head and neck tumors. The study by Rietbergen et al. showed that there is a 62% increased risk of death in patients with moderate to severe comorbidities assessed by ACE-27, compared to patients with mild or without comorbidities [28]. Yung et al. reported the prognostic significance of the comorbidities in 183 patients with head and neck tumours at the time of diagnosis and at the last post-treatment follow-up and demonstrated that the comorbidity score assessed with ACE-27 was in both cases associated with overall survival [29]. The prognostic impact of comorbidity severity (Charlson comorbidity index ≥ 6) in sinonasal carcinoma was reported in a clinical study by Suzuki et al. [14]. According to our knowledge, ACE-27 assessment of comorbidities in sinonasal carcinoma has yet to be published. A multivariate analysis of our group revealed a statistically significant impact of ACE-27 score on disease-free survival (HR: 4.479; 95% CI: 1.649–12.163; p = 0.003) and a trend toward worsening overall survival (p = 0.073) in patients with ACE score >1 (Fig. 5).
Due to the localization of the tumor near the organs at risk, the risk of severe toxicity in patients treated with curative doses of radiotherapy increases. An older retrospective study from the M.D. Anderson Cancer Center reported unilateral vision loss in 16 of the 44 patients treated with postoperative radiotherapy in whom enucleation was not part of the initial surgery [23]. Katz et al. reported unilateral amaurosis due to radiation damage in 27% of the 78 patients treated for sinonasal carcinoma, and 4 patients even developed bilateral amaurosis [10]. Le et al. in 73 patients with sinonasal carcinoma (with extension into the orbit in 52%), reported severe ocular toxicity in 26% of patients [2]. Mendenhall et al. reported in 109 patients treated with postoperative or definitive radiotherapy unilateral vision loss in 14 patients and bilateral vision loss in 1 patient; 1 patient required surgery for osteoradionecrosis of the upper jaw, 1 patient required surgery for temporal lobe necrosis. Serious complications affected 25% of patients treated with a combination approach and 19% of patients treated with radiotherapy alone [6]. In our study, we found severe late toxicity in 23% of patients. Severe grade 3/4 ocular toxicity was observed in 12% of patients, of which 3 patients experienced permanent unilateral vision loss. In total, 12 patients (15%) experienced unilateral vision loss as a result of surgical or radiation treatment.
With modern radiotherapy techniques, it is possible to obtain better dose distribution and thus minimize the risk of damage to the optic nerve, chiasma opticum, brain stem, and other healthy tissues that surround the tumour. Recent clinical studies reporting treatment results of IMRT or proton radiotherapy point to lower levels of radiation toxicity. Because of the small number of patients evaluated and the short follow-up period, outcomes of these studies has limited value. Due to the delayed onset of late toxicity, no definitive conclusions can be drawn from these evaluations [5, 15, 20, 30–32].
Conclusion
The results of the retrospective study demonstrated the high effectiveness of curative postoperative and definitive (chemo)radiotherapy in patients treated for sinonasal carcinoma with long-term locoregional and distant control. Severe acute toxicity was found in 36% of treated patients and involved not only radiation toxicity but also systemic toxicity in a large proportion of patients who received systemic treatment. Severe late toxicity was observed in 23% of patients, including unilateral vision loss in 3 patients, temporal lobe necrosis in 1 patient, and osteoradionecrosis requiring surgery in 2 patients. A multivariate analysis identified N-staging, age, comorbidity score (as evaluated by ACE-27), and initial response to treatment as the strongest prognostic factors in predicting survival.
Conflicts of interest
None declared.
Funding
None declared.